Immuneering Corp
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- IMRXImmuneering Corporation10Calm
A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
FinishedPhase 1/230 patientsMain results: Apr 30, 2025 - IMRXImmuneering Corporation0Calm
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Signing up patientsPhase 3570 patientsMain results: Jun 2028 - IMRXImmuneering Corporation0Calm
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors
Running, no new patientsPhase 1/2209 patientsMain results: Jun 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 2 purchases
- Zeskind Benjamin J.PRESIDENT AND CEO · Jun 23, 2026Bought 2,400 sharesabout $11 thousand ·
- Hall Brett MatthewCHIEF SCIENTIFIC OFFICER · Jun 15, 2026Bought 6,035 sharesabout $25 thousand ·
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.